Ning Li (Junshi)
After chiming in antibody to Covid-19 fight, Junshi drops $30M to kick off mRNA joint venture in China
A pioneering biotech in China has its eyes on mRNA.
Junshi Biosciences — which made its name as the first domestic drugmaker to steer a PD …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
